Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.
Journal: Expert opinion on drug safety
Published: August 18, 2023
Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 17, 2022
Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.
Journal: ACS infectious diseases
Published: January 31, 2022
A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis.
Journal: Frontiers in microbiology
Published: October 27, 2021
Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?
Journal: Frontiers in medicine
Published: July 22, 2021
Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!
Journal: Infectious disorders drug targets
Published: August 21, 2019
Obiltoxaximab (Anthim) for inhalation anthrax.
Journal: The Medical letter on drugs and therapeutics
Published: November 02, 2018
New FDA approved antibacterial drugs: 2015-2017.
Journal: Discoveries (Craiova, Romania)
Published: April 04, 2018
Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.
Journal: Antimicrobial agents and chemotherapy
Published: August 01, 2017
Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection.
Journal: The Annals of pharmacotherapy
Published: June 03, 2017
Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans.
Journal: Clinical pharmacology in drug development
Published: May 17, 2017
Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule.
Journal: Clinical and translational science
Published: September 02, 2016
Last Updated: 10/31/2025